Zevra Therapeutics (ZVRA) Competitors $7.64 +0.31 (+4.23%) Closing price 04:00 PM EasternExtended Trading$7.68 +0.04 (+0.52%) As of 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVRA vs. IRON, EWTX, KNSA, ANIP, IMCR, MESO, EVO, VERA, GPCR, and SPRYShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Disc Medicine (IRON), Edgewise Therapeutics (EWTX), Kiniksa Pharmaceuticals (KNSA), ANI Pharmaceuticals (ANIP), Immunocore (IMCR), Mesoblast (MESO), Evotec (EVO), Vera Therapeutics (VERA), Structure Therapeutics (GPCR), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Disc Medicine Edgewise Therapeutics Kiniksa Pharmaceuticals ANI Pharmaceuticals Immunocore Mesoblast Evotec Vera Therapeutics Structure Therapeutics ARS Pharmaceuticals Zevra Therapeutics (NASDAQ:ZVRA) and Disc Medicine (NASDAQ:IRON) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, community ranking, media sentiment, analyst recommendations and dividends. Is ZVRA or IRON more profitable? Disc Medicine has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -342.63%. Disc Medicine's return on equity of -25.24% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zevra Therapeutics-342.63% -159.54% -51.50% Disc Medicine N/A -25.24%-23.96% Do insiders and institutionals hold more shares of ZVRA or IRON? 35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 83.7% of Disc Medicine shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Comparatively, 4.2% of Disc Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, ZVRA or IRON? Zevra Therapeutics has higher revenue and earnings than Disc Medicine. Disc Medicine is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZevra Therapeutics$23.61M17.69-$46.05M-$2.24-3.41Disc MedicineN/AN/A-$76.43M-$3.99-12.45 Does the media prefer ZVRA or IRON? In the previous week, Disc Medicine had 3 more articles in the media than Zevra Therapeutics. MarketBeat recorded 7 mentions for Disc Medicine and 4 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 1.61 beat Disc Medicine's score of 1.32 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Disc Medicine 6 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor ZVRA or IRON? Disc Medicine received 22 more outperform votes than Zevra Therapeutics when rated by MarketBeat users. However, 94.74% of users gave Zevra Therapeutics an outperform vote while only 86.57% of users gave Disc Medicine an outperform vote. CompanyUnderperformOutperformZevra TherapeuticsOutperform Votes3694.74% Underperform Votes25.26%Disc MedicineOutperform Votes5886.57% Underperform Votes913.43% Do analysts prefer ZVRA or IRON? Zevra Therapeutics currently has a consensus target price of $22.29, suggesting a potential upside of 191.70%. Disc Medicine has a consensus target price of $93.80, suggesting a potential upside of 88.81%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Zevra Therapeutics is more favorable than Disc Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Which has more risk and volatility, ZVRA or IRON? Zevra Therapeutics has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. Comparatively, Disc Medicine has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. SummaryZevra Therapeutics beats Disc Medicine on 9 of the 17 factors compared between the two stocks. Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$417.75M$6.69B$5.47B$7.92BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-3.887.3222.5118.54Price / Sales17.69241.49397.62103.35Price / CashN/A65.8538.1834.62Price / Book4.476.486.734.25Net Income-$46.05M$143.41M$3.22B$248.18M7 Day Performance5.52%2.30%1.58%1.25%1 Month Performance4.37%7.14%4.05%3.76%1 Year Performance66.09%-2.61%15.75%5.28% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics2.7641 of 5 stars$7.64+4.2%$22.29+191.7%+60.0%$417.75M$23.61M-3.8820Upcoming EarningsNews CoveragePositive NewsIRONDisc Medicine2.3309 of 5 stars$45.42-1.6%$93.80+106.5%+77.5%$1.57BN/A-11.4130Upcoming EarningsNews CoveragePositive NewsEWTXEdgewise Therapeutics3.2123 of 5 stars$14.84-3.6%$40.13+170.4%-8.6%$1.55BN/A-9.8960Upcoming EarningsAnalyst ForecastShort Interest ↑News CoveragePositive NewsKNSAKiniksa Pharmaceuticals2.4929 of 5 stars$21.37+3.9%$37.17+73.9%+44.1%$1.55B$423.24M-152.63220Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageANIPANI Pharmaceuticals4.4453 of 5 stars$69.82+0.3%$80.13+14.8%+7.3%$1.52B$614.38M-126.95600Positive NewsIMCRImmunocore3.1875 of 5 stars$30.16-0.7%$60.90+101.9%-49.1%$1.51B$310.20M-31.75320Upcoming EarningsNews CoveragePositive NewsMESOMesoblast1.9193 of 5 stars$11.82-0.3%$18.00+52.3%+72.7%$1.50B$5.67M0.0080Positive NewsEVOEvotec1.8621 of 5 stars$4.22+0.2%$5.93+40.6%-19.1%$1.50B$796.97M0.004,200Upcoming EarningsShort Interest ↓VERAVera Therapeutics2.9293 of 5 stars$23.22-1.1%$64.67+178.5%-40.9%$1.48BN/A-8.9040Upcoming EarningsNews CoveragePositive NewsGPCRStructure Therapeutics2.2103 of 5 stars$23.74+0.4%$81.29+242.4%-31.5%$1.36BN/A-32.08136Upcoming EarningsNews CoverageSPRYARS Pharmaceuticals3.1301 of 5 stars$13.77-5.9%$31.00+125.1%+60.6%$1.35B$89.15M-27.0090Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies Disc Medicine Alternatives Edgewise Therapeutics Alternatives Kiniksa Pharmaceuticals Alternatives ANI Pharmaceuticals Alternatives Immunocore Alternatives Mesoblast Alternatives Evotec Alternatives Vera Therapeutics Alternatives Structure Therapeutics Alternatives ARS Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVRA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredTrump announcement boosts “next Bitcoin”President Trump just made his first big crypto move ... Announcing the creation of a national strategic re...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZVRA Stock Free ZVRA Stock Alerts